263 related articles for article (PubMed ID: 21670449)
1. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.
Millot F; Baruchel A; Guilhot J; Petit A; Leblanc T; Bertrand Y; Mazingue F; Lutz P; Vérité C; Berthou C; Galambrun C; Bernard F; Yacouben K; Bordigoni P; Edan C; Reguerre Y; Couillault G; Méchinaud F; Cayuela JM; Guilhot F
J Clin Oncol; 2011 Jul; 29(20):2827-32. PubMed ID: 21670449
[TBL] [Abstract][Full Text] [Related]
2. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and safety of imatinib in treatment of 151 chronic myeloid leukemia patients].
Zhou L; Wang AH; Wang L; You JH; Li JM; Shen ZX
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):13-7. PubMed ID: 18512309
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
6. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate.
Lakshmaiah KC; Bhise R; Purohit S; Abraham LJ; Lokanatha D; Suresh TM; Appaji L; Arunakumari BS; Govindbabu K
Leuk Lymphoma; 2012 Dec; 53(12):2430-3. PubMed ID: 22607062
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
11. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
Koh Y; Kim I; Yoon SS; Kim BK; Kim DY; Lee JH; Lee KH; Park E; Kim HJ; Sohn SK; Joo YD; Kim SJ; Chung J; Shin HJ; Kim SH; Kim CS; Song HS; Kim MK; Hyun MS; Ahn JS; Jung CW; Park S;
Ann Hematol; 2010 Jul; 89(7):725-31. PubMed ID: 20179930
[TBL] [Abstract][Full Text] [Related]
12. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
de Lavallade H; Apperley JF; Khorashad JS; Milojkovic D; Reid AG; Bua M; Szydlo R; Olavarria E; Kaeda J; Goldman JM; Marin D
J Clin Oncol; 2008 Jul; 26(20):3358-63. PubMed ID: 18519952
[TBL] [Abstract][Full Text] [Related]
13. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
Gambacorti-Passerini C; Antolini L; Mahon FX; Guilhot F; Deininger M; Fava C; Nagler A; Della Casa CM; Morra E; Abruzzese E; D'Emilio A; Stagno F; le Coutre P; Hurtado-Monroy R; Santini V; Martino B; Pane F; Piccin A; Giraldo P; Assouline S; Durosinmi MA; Leeksma O; Pogliani EM; Puttini M; Jang E; Reiffers J; Piazza R; Valsecchi MG; Kim DW
J Natl Cancer Inst; 2011 Apr; 103(7):553-61. PubMed ID: 21422402
[TBL] [Abstract][Full Text] [Related]
14. [Study on efficiency and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib].
Huang XJ; Hu JD; Li JY; Jin J; Meng FY; Shen ZX; Liu T; Wu DP; Wang JM; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):889-95. PubMed ID: 23363742
[TBL] [Abstract][Full Text] [Related]
15. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
Suttorp M; Schulze P; Glauche I; Göhring G; von Neuhoff N; Metzler M; Sedlacek P; de Bont ESJM; Balduzzi A; Lausen B; Aleinikova O; Sufliarska S; Henze G; Strauss G; Eggert A; Kremens B; Groll AH; Berthold F; Klein C; Groß-Wieltsch U; Sykora KW; Borkhardt A; Kulozik AE; Schrappe M; Nowasz C; Krumbholz M; Tauer JT; Claviez A; Harbott J; Kreipe HH; Schlegelberger B; Thiede C
Leukemia; 2018 Jul; 32(7):1657-1669. PubMed ID: 29925908
[TBL] [Abstract][Full Text] [Related]
16. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
Tauchi T; Kizaki M; Okamoto S; Tanaka H; Tanimoto M; Inokuchi K; Murayama T; Saburi Y; Hino M; Tsudo M; Shimomura T; Isobe Y; Oshimi K; Dan K; Ohyashiki K; Ikeda Y;
Leuk Res; 2011 May; 35(5):585-90. PubMed ID: 21145591
[TBL] [Abstract][Full Text] [Related]
17. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
[TBL] [Abstract][Full Text] [Related]
18. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
[TBL] [Abstract][Full Text] [Related]
19. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group.
Champagne MA; Fu CH; Chang M; Chen H; Gerbing RB; Alonzo TA; Cooley LD; Heerema NA; Oehler V; Wood C; French ME; Arceci RJ; Smith FO; Bernstein ML
Pediatr Blood Cancer; 2011 Jul; 57(1):56-62. PubMed ID: 21465636
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
